Physician profile
Richard Toof
NPI 1356389555
$8,994.66
in general payments reported to CMS, 2019-2025
30 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $1,424 · 2021: $1,758 · 2022: $1,792 · 2023: $1,080 · 2024: $1,061 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,196.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,677.62 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $1,149.37 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,006.32 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $829.27 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $632.39 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $511.44 | 2019-2025 | Jardiance, Trijardy Xr, Tradjenta |
| Allergan, INC. | $402.72 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $391.22 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $360.96 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $327.27 | 2021-2024 | Proclaim, Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $324.81 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Amgen INC. | $295.41 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $186.72 | 2019-2022 | |
| Pfizer INC. | $169.02 | 2023-2025 | |
| Eisai INC. | $118.00 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $72.44 | 2020-2021 | |
| Exact Sciences Corporation | $71.21 | 2024-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $69.17 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $57.73 | 2022 | |
| Dexcom, INC. | $48.72 | 2024-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $47.24 | 2022-2023 | Quviviq |
| Amarin Pharma, INC. | $37.60 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $35.36 | 2020 | |
| Almatica Pharma LLC | $34.82 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Janssen Pharmaceuticals, INC | $30.66 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $27.22 | 2021-2025 | Zoryve |
| Amneal Pharmaceuticals LLC | $26.70 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.67 | 2025 | Caplyta |
| Arbor Pharmaceuticals, INC. | $17.31 | 2021 | |
| Seqirus USA INC | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Toof listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.